Longduoduo Company Limited

What they do

Longduoduo is a Nevada corporation that functions exclusively as a holding company; all operations are conducted by seven limited companies organized in the PRC, owned through Hong Kong intermediaries. The operating entities sell preventive healthcare services including Immunological Ozonated Autohemotherapy, Meridian-regulating and Consciousness-restoring Iatrotechnics, Assay and PRP, and also act as a sales agent for services provided by Inner Mongolia Honghai Health Management Co., Ltd. As of March 31, 2026, the company operates through five entities in Huhhot, Ulanqab, Huhhot, Baotou and Ordos, four of the largest cities in Inner Mongolia.

Revenue drivers

• Honghai sales agency commissions — Commissions from acting as sales agent for services provided by Inner Mongolia Honghai Health Management Co., Ltd. In the quarter ended March 31, 2026, $186,042 of total revenue of $187,392, or about 99%, came from these commissions; for the year ended June 30, 2025, Honghai commissions represented over 97% of revenue.
• Preventive healthcare services — Direct sales of services such as Immunological Ozonated Autohemotherapy, Meridian-regulating and Consciousness-restoring Iatrotechnics, Assay and PRP. This line generated $1,350 in the quarter ended March 31, 2026, and cost of revenue relates solely to this service revenue.
• Third-party service provider cooperation arrangements — The company relies on third-party healthcare service providers to deliver its offered services to customers; payments to those providers make up cost of revenue.

Recent performance

For the three months ended March 31, 2026, total revenue was $187,392, down 76% from $777,720 in the prior-year quarter. Gross profit was $184,055, but the company reported a loss from operations of $197,443 and a net loss of $190,007, compared with a net loss of $116,320 a year earlier. Service revenue gross margin turned negative (a -147% deficit, or gross loss of $1,987) because healthcare service volume was limited while equipment depreciation of $2,452 was incurred. Operating expenses fell $494,597 versus the prior-year quarter. Full-year fiscal 2025 revenue was $4.3 million with net income of $460,435, down from fiscal 2024 revenue of $7.4 million and net income of $1.3 million.

Strategy

Management attributes the revenue decline to a weak economic environment and cautious consumer spending on preventive healthcare and physical examinations, and says it is adjusting operational policies while awaiting an economic recovery. The company states it incurred significant marketing expense to establish its brand and will continue to invest heavily in advertising and promotion in the near future with the goal of revitalizing its marketing operations.

Risks

• Customer concentration — Over 97% of revenue in the year ended June 30, 2025 came from Inner Mongolia Honghai Health Management Co., Ltd., so termination of that relationship would likely seriously harm financial results.
• Sales agency agreement expiry — The Sales Agency Agreements with Honghai terminate in June 2026, and there is no certainty the relationship continues past that date.
• Third-party service provider liability — The company relies on third-party healthcare providers to deliver services and could be liable and suffer reputational harm if a provider performs poorly or harms a customer.
• PRC regulatory and distribution risk — As a Nevada holding company with all operations in the PRC, Longduoduo depends on distributions from its Chinese subsidiary, and Chinese regulatory authorities could prevent those distributions to the Nevada parent.

Outlook

Management says the weak economic environment has curbed consumer spending on preventive healthcare services and physical examinations, and that recent government policies to promote recovery may take time to improve conditions. The company expects to continue investing heavily in advertising and promotion to rebuild marketing operations, while adjusting operational policies.